Abstract:Heat shock proteins (HSP) have been revealed to interact with antigen-presenting cells and have potent adjuvant capability to induce antigen-specific CD8(+) CTL and Th1 responses. Our previous work shows how Hsp70-like protein 1 (Hsp70L1), as a new member of the Hsp70 subfamily, acts as potent Th1 adjuvant. Here, we report the efficient induction of tumor antigen-specific immune response by dendritic cells pulsed with recombinant fusion protein of Hsp70L1 and CEA(576-669) fragment of the carcinoembryonic antigen (CEA) containing CAP-1 (a HLA-A2-restricted CTL epitope). Fusion protein CEA(576-669)-Hsp70L1 can promote dendritic cell maturation and activate dendritic cells to produce cytokines, such as interleukin-12, interleukin-1 beta, and tumor necrosis factor-a, and chemokines, such as macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and regulated on activation, normal T expressed and secreted, indicating the adjuvant ability of Hsp70L1 in the fusion protein. CEA-specific HLA-A2.1-restricted CD8(+) CTLs either from patients with CEA(+)/HLA-A2.1(+) colon carcinoma or from splenocytes of immunized HLA-A2.1/K-b transgenic mice can be generated more efficiently after stimulations or immunizations with dendritic cells pulsed by CEA(576-669)-Hsp70L1 than with dendritic cells pulsed by CEA(576-669) alone, resulting in secreting more Th1 cytokine IFN-gamma and killing target cells more potently in an antigen-specific and HLA-A2.1-restricted manner. Adoptive transfer of splenocytes from transgenic mice immunized with CEA(576-669)-Hsp70L1-pulsed dendritic cells can inhibit tumor growth and prolong survival in nude mice bearing CEA*/HLA-A2.1(+) human colon carcinoma more markedly. Therefore, Hsp70L1 has potent adjuvant effect in form of fusion protein, indicating that Hsp70L1 may be widely used as Th1 adjuvant to prepare antigenic fusion protein for the therapeutics of cancer or infectious diseases.

Heat Shock Fusion Protein Induces Both Specific And Nonspecific Anti-Tumor Immunity

Prokaryotic Expression, Purification of HSP65-MUC1 VNTR2 Fusion Protein and Primary Research on Its Tumoricidal Effect

Antitumor therapeutic effect induced by intestine- carcinoma cells vaccine expressing membrane- bound heat shock protein 70

Pre-Clinical Safety Evaluation Of Heat Shock Protein 65-Muc1 Peptide Fusion Protein

Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.

Heat Shock Protein 70 / MAGE-1 Tumor Vaccine Can Enhance the Potency of MAGE-1–specific Cellular Immune Responses in Vivo

Dendritic-Tumor Fusion Cells Derived Heat Shock Protein70-Peptide Complex Has Enhanced Immunogenicity

Heat Shock Protein 70/MAGE-3 Fusion Protein Vaccine Can Enhance Cellular and Humoral Immune Responses to MAGE-3 in Vivo.

Fusion Proteins of Hsp70 with Tumor-Associated Antigen Acting As A Potent Tumor Vaccine and the C-Terminal Peptide-Binding Domain of Hsp70 Being Essential in Inducing Antigen-Independent Anti-Tumor Response in Vivo

Fusion Protein of ATPase Domain of Hsc70 with TRP2 Acting As a Tumor Vaccine Against B16 Melanoma.

Hsp70-Like Protein 1 Fusion Protein Enhances Induction Of Carcinoembryonic Antigen-Specific Cd8(+) Ctl Response By Dendritic Cell Vaccine

MUC1 and maltose‑binding protein recombinant fusion protein combined with Bacillus Calmette‑Guerin induces MUC1‑specific and nonspecific anti‑tumor immunity in mice.

Primary Screening of Antitumor Immunoadjuvants Combined with Heat Shock Fusion Protein

Mf59 Formulated With Cpg Odn As A Potent Adjuvant Of Recombinant Hsp65-Muc1 For Inducing Anti-Muc1(+) Tumor Immunity In Mice

Fusion of Hsp70 to Mage-a1 enhances the potency of vaccine-specific immune responses

Enhanced antitumor immunity of nanoliposome-encapsulated heat shock protein 70 peptide complex derived from dendritic tumor fusion cells

The Fusion Protein of Hsp65 with Tandem Repeats of Beta-Hcg Acting As A Potent Tumor Vaccine in Suppressing Hepatocarcinoma

Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor

Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.

Comparison of anti-tumor effect between human MUC1-MBP and mouse Mucl-MBP fusion protein vaccine

VEGF165b mutant can be used as a protein carrier to form a chimeric tumor vaccine with Mucin1 peptide to elicit an anti-tumor response